Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.

devices, tools, and enabling technologies”, but will look at investments more broadly across healthcare. Aberman was at Regeneron for seven years, rising to the role of senior vice president of ...

It provides a range of software, services, and devices for ... decision regarding the Eylea biosimilar case as a modest setback but believes it does not overshadow Regeneron’s long-term growth ...

Boston Scientific makes surgical devices and medical equipment to treat ... due to wholesaler destocking. Regeneron Pharmaceuticals makes drugs to treat eye diseases, allergies, inflammation ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

Opthea's sozinibercept and Unity's UBX1325 fail to match Regeneron's Eylea in separate eye disease trials; Opthea faces ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...